Back

NeuroSense unveils three-part PrimeC ALS plan for faster approval path

Verifying
  • NeuroSense redesigned PrimeC's ALS development program around three focused clinical and analytical studies.
  • December 2026 remains NeuroSense's target for submitting PrimeC's Canadian New Drug Submission.
  • NeuroSense has FDA clearance to initiate the pivotal Phase 3 PARAGON trial.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.